SCHEMBL2823972

SCHEMBL2823972

CCc1ccc(S(=O)(=O)NC2c3cc(CC(=O)N4CCN(Cc5ccccc5)CC4)ccc3OC(C)(C)C2O)cc1

nearest known ligand 0.64

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ KCNA5 P22460 19/20 0.64
▸ KDM4E B2RXH2 1/20 0.51
▸ ALDH1A1 P00352 1/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4197961 0.94 KCNA5 (0.58) KCNA5ALDH1A1SMN1; SMN2
SCHEMBL4197964 0.94 KCNA5 (0.58) KCNA5ALDH1A1SMN1; SMN2
SCHEMBL2828831 0.92 KCNA5 (0.55) KCNA5
SCHEMBL2827259 0.91 KCNA5 (0.54) KCNA5KDM4EALDH1A1
SCHEMBL2825588 0.91 KCNA5 (0.54) KCNA5KDM4EALDH1A1
Hydrochloric Acid SCHEMBL3286007 0.91 KCNA5 (0.54) KCNA5KDM4EALDH1A1
SCHEMBL2828528 0.90 KCNA5 (0.54) KCNA5KDM4EALDH1A1
SCHEMBL2825424 0.82 KCNA5 (0.69) KCNA5
SCHEMBL4194462 0.81 SMN1; SMN2 (0.47) KCNA5KDM4EALDH1A1SMN1; SMN2
SCHEMBL4194460 0.81 SMN1; SMN2 (0.47) KCNA5KDM4EALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273905-B2 Aminoalkyl-amidomethyl-substituted 2-(4-sulphonylamino)-3-hydroxy-3,4-dihydro-2H-chroman-6-yl derivatives ABBOTT PRODUCTS GMBH (DE) 2012-09-25 — — US claimed
CN-101160301-B Aminoalkyl-amidomethyl-substituted 2- (4-sulfonylamino) -3-hydroxy-3, 4-dihydro-2H-chromen-6-yl derivatives and their use as potassium channel blockers SOLVAY PHARM BV 2012-03-28 — — CN claimed
EP-1871758-B1 AMINOALKYL-AMIDOMETHYL-SUBSTITUTED 2- (4-SULPHONYLAMINO) -3-HYDROXY-3 , 4-DIHYDRO-2H-CROMEN-6-YL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL BLOCKERS ABBOTT PRODUCTS GMBH (DE) 2010-08-25 — — EP claimed
US-20090203686-A1 Aminoalkyl-Amidomethyl-Substituted 2-(4-Sulphonylamino)- 3-Hydroxy-3,4-Dihydro-2H-Chroman-6-yl Derivatives SOLVAY PHARMACEUTICALS GMBH (DE) 2009-08-13 — — US claimed
CN-101160301-A Aminoalkyl-amidomethyl-substituted 2- (4-sulfonylamino) -3-hydroxy-3, 4-dihydro-2H-chromen-6-yl derivatives and their use as potassium channel blockers SOLVAY PHARM GMBH (DE) 2008-04-09 — — CN claimed
EP-1871758-A1 AMINOALKYL-AMIDOMETHYL-SUBSTITUTED 2- (4-SULPHONYLAMINO) -3-HYDROXY-3 , 4-DIHYDRO-2H-CROMEN-6-YL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL BLOCKERS Solvay Pharmaceuticals GmbH (DE) 2008-01-02 — — EP claimed
US-20060252821-A1 Aminoalkyl-amidomethyl-substituted 2-(4-sulphonylamino)-3-hydroxy-3,4-dihydro-2H-chroman-6-yl derivatives SOLVAY PHARMACEUTICALS GMBH 2006-11-09 — — US claimed
WO-2006108837-A1 AMINOALKYL-AMIDOMETHYL-SUBSTITUTED 2- (4-SULPHONYLAMINO) -3-HYDROXY-3 , 4-DIHYDRO-2H-CROMEN-6-YL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL BLOCKERS SOLVAY PHARMACEUTICALS GMBH (DE) 2006-10-19 — — WO claimed
US-8273905-B2 Aminoalkyl-amidomethyl-substituted 2-(4-sulphonylamino)-3-hydroxy-3,4-dihydro-2H-chroman-6-yl derivatives ABBOTT PRODUCTS GMBH (DE) 2012-09-25 — — US disclosed
CN-101160301-B Aminoalkyl-amidomethyl-substituted 2- (4-sulfonylamino) -3-hydroxy-3, 4-dihydro-2H-chromen-6-yl derivatives and their use as potassium channel blockers SOLVAY PHARM BV 2012-03-28 — — CN disclosed
EP-1871758-B1 AMINOALKYL-AMIDOMETHYL-SUBSTITUTED 2- (4-SULPHONYLAMINO) -3-HYDROXY-3 , 4-DIHYDRO-2H-CROMEN-6-YL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL BLOCKERS ABBOTT PRODUCTS GMBH (DE) 2010-08-25 — — EP disclosed
US-7714150-B2 Aminoalkyl-amidomethyl-substituted 2-(4-sulphonylamino)-3-hydroxy-3,4-dihydro-2H-chroman-6-yl derivatives SOLVAY PHARMACEUTICALS GMBH (DE) 2010-05-11 — — US disclosed
US-20090203686-A1 Aminoalkyl-Amidomethyl-Substituted 2-(4-Sulphonylamino)- 3-Hydroxy-3,4-Dihydro-2H-Chroman-6-yl Derivatives SOLVAY PHARMACEUTICALS GMBH (DE) 2009-08-13 — — US disclosed
CN-101160301-A Aminoalkyl-amidomethyl-substituted 2- (4-sulfonylamino) -3-hydroxy-3, 4-dihydro-2H-chromen-6-yl derivatives and their use as potassium channel blockers SOLVAY PHARM GMBH (DE) 2008-04-09 — — CN disclosed
EP-1871758-A1 AMINOALKYL-AMIDOMETHYL-SUBSTITUTED 2- (4-SULPHONYLAMINO) -3-HYDROXY-3 , 4-DIHYDRO-2H-CROMEN-6-YL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL BLOCKERS Solvay Pharmaceuticals GmbH (DE) 2008-01-02 — — EP disclosed
US-20060252821-A1 Aminoalkyl-amidomethyl-substituted 2-(4-sulphonylamino)-3-hydroxy-3,4-dihydro-2H-chroman-6-yl derivatives SOLVAY PHARMACEUTICALS GMBH 2006-11-09 — — US disclosed
WO-2006108837-A1 AMINOALKYL-AMIDOMETHYL-SUBSTITUTED 2- (4-SULPHONYLAMINO) -3-HYDROXY-3 , 4-DIHYDRO-2H-CROMEN-6-YL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL BLOCKERS SOLVAY PHARMACEUTICALS GMBH (DE) 2006-10-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060252821-A1 Aminoalkyl-amidomethyl-substituted 2-(4-sulphonylamino)-3-hydroxy-3,4-dihydro-2H-chroman-6-yl derivatives H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PRMT9, ABCC9 KCNA5 929/4885KDM4E 814/4885ALDH1A1 737/4885
US-20090203686-A1 Aminoalkyl-Amidomethyl-Substituted 2-(4-Sulphonylamino)- 3-Hydroxy-3,4-Dihydro-2H-Chroman-6-yl Derivatives H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PRMT9, ARG1 KCNA5 1080/4885KDM4E 920/4885ALDH1A1 681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback